Compare · IMMU vs ORKA
IMMU vs ORKA
Side-by-side comparison of Immunomedics, Inc. (IMMU) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMMU and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $6.74B.
- ORKA has hit the wire 11 times in the past 4 weeks while IMMU has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for IMMU).
- Company
- Immunomedics, Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- -
- $6.74B
- 1M return
- -
- +12.94%
- 1Y return
- -
- +588.78%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
Latest IMMU
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- NorthStar Appoints Peter Pfreundschuh to Board of Managers
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- SEC Form SC 13G/A filed
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update